OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab
(State on share capital and voting rights in FR)
You confirm that you have read our privacy policy. You can unsubscribe at any time by using the unsubscribe links.